Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials
Joint Authors
Ronellenfitsch, Ulrich
Hofheinz, Ralf-Dieter
Kubicka, S.
Falcone, A.
Burkholder, I.
Hacker, U. T.
Source
Gastroenterology Research and Practice
Issue
Vol. 2016, Issue 2016 (31 Dec. 2015), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-08-30
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit.
We synthesized the available evidence in a meta-analysis.
Patients and Methods.
We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression.
Eligible studies were randomized phase II/III trials.
Primary endpoints were overall survival (OS) and progression-free survival (PFS).
Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression.
Results.
Eight studies (3,668 patients) were included.
Continuing antiangiogenic treatment beyond progression significantly improved PFS (HR 0.64; 95%-CI, 0.55–0.75) and OS (HR 0.83; 95%-CI, 0.76–0.89).
PFS was significantly improved in all subgroups with comparable HR.
OS was improved in all subgroups stratified by age, gender, and ECOG status.
The rate of patients achieving at least stable disease was improved with an OR of 2.25 (95%-CI, 1.41–3.58).
Conclusions.
This analysis shows a significant PFS and OS benefit as well as a benefit regarding disease stabilization when using antiangiogenic drugs beyond progression in mCRC.
Future studies should focus on the optimal sequence of administering antiangiogenic drugs.
American Psychological Association (APA)
Hofheinz, Ralf-Dieter& Ronellenfitsch, Ulrich& Kubicka, S.& Falcone, A.& Burkholder, I.& Hacker, U. T.. 2016. Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104830
Modern Language Association (MLA)
Hofheinz, Ralf-Dieter…[et al.]. Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice Vol. 2016, no. 2016 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1104830
American Medical Association (AMA)
Hofheinz, Ralf-Dieter& Ronellenfitsch, Ulrich& Kubicka, S.& Falcone, A.& Burkholder, I.& Hacker, U. T.. Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. Gastroenterology Research and Practice. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104830
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1104830